BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy
Open Access
- 18 February 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (5) , 597-611
Abstract
Immune checkpoint therapy (ICT) using antibody blockade of programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can provoke T cell–dependent antitumor activity that generates durable clinical responses in some patients. The epigenetic and transcriptional features that T cells require for efficacious ICT remain to be fully elucidated. Herein, we report that anti–PD-1 and anti–CTLA-4 ICT induce upregulation of the transcription factor BHLHE40 in tumor antigen–specific CD8+ and CD4+ T cells and that T cells require BHLHE40 for effective ICT in mice bearing immune-edited tumors. Single-cell RNA sequencing of intratumoral immune cells in BHLHE40-deficient mice revealed differential ICT-induced immune cell remodeling. The BHLHE40-dependent gene expression changes indicated dysregulated metabolism, NF-κB signaling, and IFNγ response within certain subpopulations of CD4+ and CD8+ T cells. Intratumoral CD4+ and CD8+ T cells from BHLHE40-deficient mice exhibited higher expression of the inhibitory receptor gene Tigit and displayed alterations in expression of genes encoding chemokines/chemokine receptors and granzyme family members. Mice lacking BHLHE40 had reduced ICT-driven IFNγ production by CD4+ and CD8+ T cells and defects in ICT-induced remodeling of macrophages from a CX3CR1+CD206+ subpopulation to an iNOS+ subpopulation that is typically observed during effective ICT. Although both anti–PD-1 and anti–CTLA-4 ICT in BHLHE40-deficient mice led to the same outcome—tumor outgrowth—several BHLHE40-dependent alterations were specific to the ICT that was used. Our results reveal a crucial role for BHLHE40 in effective ICT and suggest that BHLHE40 may be a predictive or prognostic biomarker for ICT efficacy and a potential therapeutic target.Keywords
All Related Versions
Funding Information
- CPRIT (RR190017)
- NIH NCI (P30CA016672, R01AI113118, R01AI132653, U01CA247760)
- NCI NIH (K12CA167540)
- Damon Runyon Cancer Research Foundation (DRG-2427-21)
- NCI Cancer Center (P30CA16672)
- NCI (CA016672)
- NIH (1S10OD024977-01)
- NCI NIH Cancer Center (P30CA91842)
This publication has 56 references indexed in Scilit:
- Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapyNature Reviews Cancer, 2014
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive MelanomaJournal of Clinical Oncology, 2013
- CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell responseJournal of Experimental Medicine, 2013
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T CellsCancer Immunology Research, 2013
- T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouseJournal of Experimental Medicine, 2011
- The Role of the Basic Helix-Loop-Helix Transcription Factor Dec1 in the Regulatory T CellsThe Journal of Immunology, 2010
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesJournal of Experimental Medicine, 2009
- mSharp-1/DEC2, a Basic Helix-Loop-Helix Protein Functions as a Transcriptional Repressor of E Box Activity and Stra13 ExpressionJournal of Biological Chemistry, 2003
- Identification of Functional Hypoxia Response Elements in the Promoter Region of the DEC1 and DEC2 GenesJournal of Biological Chemistry, 2002
- Cloning and Characterization of the Genes Encoding the Murine Homoloties of the Human Melanoma Antigens MARTI and gp100Journal of Immunotherapy, 1997